Syndax Q4 2022 net loss $39.2M; revumenib topline data expected Q3 2023

Syndax Pharmaceuticals Inc

2022-FY EPS reported -$2.46

Net loss of $39.2M ($0.62 per share) for Q4 2022 vs net gain of $96.2M ($1.81) in Q4 2021.
Cash and investments $481.3M as of Dec 31, 2022; raised $162M from December stock offering.
Revumenib topline data from AUGMENT-101 KMT2Ar cohort expected Q3 2023; NDA filing by year-end 2023.
Axatilimab topline data from pivotal AGAVE-201 expected mid-2023; BLA filing by year-end 2023.
Guidance: Full year 2023 total operating expenses $225-240M, R&D $160-175M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Syndax Pharmaceuticals Inc reported financial results for the fourth quarter and full year ended December 31, 2022.

Period: the fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

View on SEC.gov

Browse all earnings releases →

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0000950170-23-005069

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.